Hong Chen
Director - Evaluation & Search Novo Nordisk
Hong Chen is a seasoned professional in the biomedical field, currently serving as the Director of Search & Evaluation at Novo Nordisk since October 2021. Her extensive experience includes roles at Novartis Institutes for BioMedical Research, where she advanced drug discovery projects and provided scientific support for clinical phases. Hong Chen holds a PhD in Molecular Genetics from Baylor College of Medicine and a Bachelor of Science in Biology from Peking University. Her postdoc training was completed at Harvard Medical School.
Seminars
Thursday 16th July 2026
Panel Discussion: The 2030 Vision – Shifting from Acute Weight Loss to Sustainable Disease Modification & Integrated Cardiometabolic Health
3:10 pm
- Prioritizing the resolution of co-morbidities such as MASH, CKD, and heart failure to move beyond BMI reduction as the sole metric of clinical success, establishing obesity drugs as essential “foundation therapies” for lifelong cardiometabolic protection
- Implementing evidence-based “step-down” protocols, transitioning patients from high-dose injectable peptides to low-dose oral small molecules or RNA-based silencers to suppress the biological “rebound effect” after reaching goal weight for durable weight stability and higher long-term therapy persistence
- Integrating longitudinal data on physical function, hospitalization rates, and employment status to quantify the total economic value of long-term obesity treatment, providing a robust scientific justification for expanded reimbursement and universal patient access across diverse socioeconomic populations
